Novo Nordisk’s stock rises 10% by end of 2026 due to Wegovy pill dema…

Novo Nordisk’s stock is expected to benefit from increased demand for the oral Wegovy pill in the UK, which offers a needle-free alternative to the injectable version. Analysts project that the convenience factor will drive higher adoption rates among consumers.

earnings · Prediction Market

Implied probability (Yes)

70%

Closes

2026-12-31

More earnings markets

• Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
• Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
• Lime achieves profitability within 12 months post-IPO — 55% Yes
• Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
• SpaceX IPO will raise over $50 billion in its debut — 70% Yes
• Cerebras IPO to price above midpoint by June 30, 2026 — 70% Yes
• Kodiak AI reports positive adjusted EBITDA within 12 months — 55% Yes
• Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes

Browse all earnings markets →